Acorda Therapeutics, Inc. (ACOR)

NASDAQ: ACOR · IEX Real-Time Price · USD
14.99
+0.49 (3.38%)
At close: Sep 29, 2023, 4:00 PM
15.60
+0.61 (4.07%)
After-hours: Sep 29, 2023, 5:12 PM EDT
3.38%
Market Cap 19.48M
Revenue (ttm) 116.91M
Net Income (ttm) -20.92M
Shares Out 1.30M
EPS (ttm) -5.75
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 3,342
Open 15.03
Previous Close 14.50
Day's Range 14.05 - 15.03
52-Week Range 5.60 - 24.80
Beta 1.43
Analysts n/a
Price Target n/a
Earnings Date Oct 31, 2023

About ACOR

Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. The company's product pipeline includes Cimaglermin alfa (GGF2), a member ... [Read more]

Sector Healthcare
IPO Date Feb 10, 2006
Employees 111
Stock Exchange NASDAQ
Ticker Symbol ACOR
Full Company Profile

Financial Performance

In 2022, ACOR's revenue was $118.57 million, a decrease of -8.14% compared to the previous year's $129.07 million. Losses were -$65.92 million, -36.59% less than in 2021.

Financial Statements

News

Acorda Therapeutics Reports Second Quarter 2023 Financial Results

PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Reports Second Quarter 2023 Financial Results.

7 weeks ago - Business Wire

Acorda Therapeutics Announces Launch of New INBRIJA® Campaign: “For The Fighters™”

PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Announces Launch of New INBRIJA® Campaign: “For The FightersTM”.

2 months ago - Business Wire

Acorda Second Quarter 2023 Update: Webcast/Conference Call Scheduled for August 8, 2023

PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Second Quarter 2023 Update: Webcast/Conference Call Scheduled for August 8, 2023.

2 months ago - Business Wire

Tom Burns Elected to the Acorda Therapeutics Board of Directors

PEARL RIVER, N.Y.--(BUSINESS WIRE)--Tom Burns Elected to the Acorda Therapeutics Board of Directors.

3 months ago - Business Wire

Acorda Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement.

3 months ago - Business Wire

Acorda Therapeutics Regains Compliance with Nadaq Minimum Bid Price Requirement

PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Regains Compliance with Nadaq Minimum Bid Price Requirement.

3 months ago - Business Wire

Acorda Therapeutics Announces Completion of 1-for-20 Reverse Stock Split

PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Announces Completion of 1-for-20 Reverse Stock Split.

4 months ago - Business Wire

Acorda Therapeutics to Conduct 1-for-20 Reverse Stock Split

PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics to Conduct 1-for-20 Reverse Stock Split.

4 months ago - Business Wire

Acorda Therapeutics CEO Ron Cohen, M.D., to Hold Virtual Company Presentation and Q&A

PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics CEO Ron Cohen, M.D., to Hold Virtual Company Presentation and Q&A.

4 months ago - Business Wire

Acorda Therapeutics Reports First Quarter 2023 Financial Results

PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Reports First Quarter 2023 Financial Results.

5 months ago - Business Wire

Acorda Therapeutics to Make June 2023 $6.2 Million Interest Payment on Secured Debt in Cash

PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics to Make June 2023 $6.2 Million Interest Payment on Secured Debt in Cash.

5 months ago - Business Wire

Acorda Therapeutics and Chance Pharmaceuticals Announce Agreement to Commercialize INBRIJA® in China

PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics and Chance Pharmaceuticals Announce Agreement to Commercialize INBRIJA® in China.

5 months ago - Business Wire

Acorda First Quarter 2023 Update: Webcast/Conference Call Scheduled for May 11, 2023

PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda First Quarter 2023 Update: Webcast/Conference Call Scheduled for May 11, 2023.

5 months ago - Business Wire

Acorda Therapeutics to Present INBRIJA® Data at the American Academy of Neurology Annual Meeting

PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics to Present INBRIJA® Data at the American Academy of Neurology Annual Meeting.

5 months ago - Business Wire

Acorda Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today reported its financial results for the fourth quarter and full year ended December 31, 2022.

7 months ago - Business Wire

Acorda Therapeutics to Present at Sequire Biotechnology Conference

PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (NASDAQ: ACOR) announced that Ron Cohen, M.D., Acorda's President and Chief Executive Officer, will make a virtual presentation at the S...

8 months ago - Business Wire

Acorda Therapeutics Announces New Agreement with Catalent for Long-Term Global Supply of INBRIJA®

PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that on December 31, 2022 it entered into a new long-term global supply agreement with Catalent for the m...

9 months ago - Business Wire

Acorda Therapeutics Announces Revised Long-Term Financial Guidance

PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it has revised and updated the long-term financial guidance most recently included in its November 1...

Other symbols: M
10 months ago - Business Wire

Acorda Therapeutics Receives Nasdaq Listing Determination Letter and Plans to Request a Hearing

PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it was notified by the Listing Qualifications Staff of The Nasdaq Stock Market LLC that, due to the ...

10 months ago - Business Wire

Acorda Therapeutics Makes December 2022 $6.2 Million Interest Payment on Secured Debt in Cash

PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it made a cash interest payment of approximately $6.2 million due on December 1, 2022 under its Conv...

10 months ago - Business Wire

Acorda Therapeutics Announces Passage of Reverse Stock Split Proposal at its Special Meeting of Stockholders

PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that the Company's stockholders approved the Reverse Stock Split proposal at its reconvened Special Meeti...

11 months ago - Business Wire

Acorda Therapeutics Announces Adjournment of Special Meeting of Stockholders

Acorda Therapeutics, Inc. (Nasdaq: ACOR) convened its Special Meeting of Stockholders on November 4, 2022, and a proposal to adjourn the meeting was approved in order to provide stockholders with addi...

11 months ago - Business Wire

Acorda Therapeutics Reports Third Quarter 2022 Financial Results

PEARL RIVER, N.Y.

11 months ago - Business Wire